Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults

Chichester, Jessica A.; Green, Brian J.; Jones, R. Mark; Shoji, Yasuhiro; Miura, Kazutoyo; Long, Carole A.; Lee, Cynthia; Ockenhouse, Christian F.; Morin, Merribeth J.; Streatfield, Stephen J.; Yusibov, Vidadi

doi:10.1016/j.vaccine.2018.08.033

Cited by 100 publications

(69 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The existing vaccine, RTS,S, has demonstrated only limited efficacy in clinical trials [17]. A recent publication [53] summarizes the results of a Phase I study assessing a malaria transmission-blocking vaccine based on a recombinant fusion of the P. falciparum antigen Pfs25 with the plant virus AlMV. Vaccine candidates produced in whole plants under cGMP conditions demonstrate acceptable safety and tolerability and induce antibodies against Pfs25, depending on the injected vaccine dose.…”

Section: Plant Vlp-derived Vaccines Against Infectious Diseasesmentioning

confidence: 99%

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

Baļķe

Zeltiņš

2020

Viruses

View full text Add to dashboard Cite

Vaccination is one of the most effective public health interventions of the 20th century. All vaccines can be classified into different types, such as vaccines against infectious diseases, anticancer vaccines and vaccines against autoimmune diseases. In recent decades, recombinant technologies have enabled the design of experimental vaccines against a wide range of diseases using plant viruses and virus-like particles as central elements to stimulate protective and long-lasting immune responses. The analysis of recent publications shows that at least 97 experimental vaccines have been constructed based on plant viruses, including 71 vaccines against infectious agents, 16 anticancer vaccines and 10 therapeutic vaccines against autoimmune disorders. Several plant viruses have already been used for the development of vaccine platforms and have been tested in human and veterinary studies, suggesting that plant virus-based vaccines will be introduced into clinical and veterinary practice in the near future.

show abstract

Section: Plant Vlp-derived Vaccines Against Infectious Diseasesmentioning

confidence: 99%

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

Baļķe

Zeltiņš

2020

Viruses

View full text Add to dashboard Cite

show abstract

“…In contrast to the PEV and BSV vaccines, which have already been assayed in completed Phase III trials, the assays of the Pfs25 antigen are in early development and so far, have only completed Phase I trial assays, though with success. In one of them, the Pfs25 protein was engineered as a VLP, manufactured in Nicotiana benthamiana plants, and was formulated with Alhydrogel (63). In a second Phase I trial, Pfs25 was conjugated to the recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa (64).…”

Section: Tbv Vaccinesmentioning

confidence: 99%

The Delay in the Licensing of Protozoal Vaccines: A Comparative History

Palatnik-de-Sousa

Nico

2020

Front. Immunol.

View full text Add to dashboard Cite

“…NCT02013687). The initial trials using Alhydrogel formulations of Pfs-EPA or Pfs25-VLP showed that they were safe but did not stimulate robust TBA titers, and these results have led to the testing of alternative adjuvants, including AS01 (113)(114)(115).…”

Section: Gametocyte/gamete Antigens Pfs230 Pfs48/45 Pfs47 and Hap2mentioning

confidence: 99%

Transmission-Blocking Vaccines: Old Friends and New Prospects

et al. 2019

View full text Add to dashboard Cite

In the progression of the life cycle of Plasmodium falciparum, a small proportion of asexual parasites differentiate into male or female sexual forms called gametocytes. Just like their asexual counterparts, gametocytes are contained within the infected host's erythrocytes (RBCs). However, unlike their asexual partners, they do not exit the RBC until they are taken up in a blood meal by a mosquito. In the mosquito midgut, they are stimulated to emerge from the RBC, undergo fertilization, and ultimately produce tens of thousands of sporozoites that are infectious to humans. This transmission cycle can be blocked by antibodies targeting proteins exposed on the parasite surface in the mosquito midgut, a process that has led to the development of candidate transmission-blocking vaccines (TBV), including some that are in clinical trials. Here we review the leading TBV antigens and highlight the ongoing search for additional gametocyte/gamete surface antigens, as well as antigens on the surfaces of gametocyte-infected erythrocytes, which can potentially become a new group of TBV candidates.

show abstract

Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults

Cited by 100 publications

References 32 publications

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

The Delay in the Licensing of Protozoal Vaccines: A Comparative History

Transmission-Blocking Vaccines: Old Friends and New Prospects

Contact Info

Product

Resources

About